| __timestamp | Novartis AG | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14993000000 | 7751000 |
| Thursday, January 1, 2015 | 14247000000 | 10251000 |
| Friday, January 1, 2016 | 14192000000 | 9575000 |
| Sunday, January 1, 2017 | 14997000000 | 10912000 |
| Monday, January 1, 2018 | 16471000000 | 11049000 |
| Tuesday, January 1, 2019 | 14369000000 | 11646000 |
| Wednesday, January 1, 2020 | 14197000000 | 13265000 |
| Friday, January 1, 2021 | 14886000000 | 25805000 |
| Saturday, January 1, 2022 | 14253000000 | 35182000 |
| Sunday, January 1, 2023 | 12489000000 | 94999000 |
| Monday, January 1, 2024 | 12566000000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Novartis AG and Viridian Therapeutics, Inc. over the past decade. Novartis, a global healthcare giant, has seen its SG&A expenses fluctuate, peaking in 2018 with a 10% increase from the previous year, before declining by 24% in 2023. In contrast, Viridian Therapeutics, a smaller player, has experienced a dramatic rise in SG&A expenses, surging by over 1,100% from 2014 to 2023. This stark contrast highlights the differing strategies and challenges faced by large and small pharmaceutical companies. As Novartis focuses on streamlining operations, Viridian's growth trajectory suggests aggressive expansion efforts. Understanding these trends provides valuable insights into the strategic priorities and financial health of these industry players.
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Comparing SG&A Expenses: Novartis AG vs Cytokinetics, Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Novartis AG and Jazz Pharmaceuticals plc
SG&A Efficiency Analysis: Comparing Novartis AG and Amneal Pharmaceuticals, Inc.
Novartis AG vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Rhythm Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.